Skip to main content
OpenTrials
Completed

NCT Number: NCT06573502

Platelet Rich Plasma Combined With Platelet Rich Fibrin in Management of Temporomandibular Joint Osteoarthritis

Studying effectiveness of prp with prf comparing with prp or prf for mangement of tmj osteoarthritis as result in pain and mandibular movement in adult pt

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cairo university

Cairo, Egypt

About this study

45 pt assigned for the study , divided in to three gruops to comparing new combination of prp with prf in management of TMJ OA

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult pt with OA

Exclusion criteria

Medicaly compromised

Treatment and study plan

Prp with prf or prp or prf

Combination Product

Combination

Primary outcomes

  1. Pain severty

    Time frame: 6 months

    Visual analog scale measure for pain most sever pain take 10 minimum pain take 0

Secondary outcomes

  1. Maximum mouth opening

    Time frame: 6 months

    Measured with calipar

Sponsors and collaborators

Lead sponsor

Aliaa Babekir Ahmed Mohamed

Other

Registry information

Official study title

Assessment of Platelet Rich Plasma With Injectable Platelet Rich Fibrin VS Platelet Rich Plasma Vs Platelet Rich Fibrin in Management of Temporomandibular Joint Osteoarthritis

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 27, 2024
Registry last updated
Dec 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.